Nearly All Nursing Homes Fail Federal Rules on Anti-Psychotics
A year ago, the OIG, which is a branch of the U.S. Department of Health and Human Services, published a report saying that about half of anti-psychotic medications given to Medicare beneficiaries in nursing homes were not for medically accepted indications, and one in five were not given in accordance with federal safeguards to protect residents from unnecessary use.
The latest report takes the investigation one step further by looking at whether all four requirements in the process of determining appropriate use of those anti-psychotics in nursing homes were met.
The OIG recommends that the Centers for Medicare & Medicaid Services should do more to improve the process, specifically by modifying the survey "to target a small subsample of residents receiving anti-psychotic drugs focusing on the quality of care for these particularly vulnerable residents."
Also, CMS could require that nursing facilities document any efforts “to include the participation of residents, their families, or their legal representatives" in developing care plans.
- Healthcare Leaders Seek Strategic Sweet Spot
- 3 Reasons Wellness Programs Fail
- CMS Issues Health Insurance Exchange Proposed Rules
- Patients Shoulder Nearly 25% of Medical Bills
- ACOs Widespread, Yet Challenged
- MGMA: Physician Compensation Increasingly Based on Quality Measures
- 6 CNO-to-CEO Strategies
- HFMA: Patient Financial Interaction Guidelines Sharpened
- PwC: Pace of Rising Medical Costs Slowing
- HFMA: Revenue Cycle, Reimbursements Share the Spotlight